Should I Buy MLSS? MLSS 2026 Analysis

Should You Buy Milestone Scientific Inc (MLSS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.260

1 Day change

3.53%

52 Week Range

1.280

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: trend/momentum is bearish (SMA_200 > SMA_20 > SMA_5) and MACD remains below zero.
No Intellectia edge today (no AI Stock Picker / no SwingMax), so there’s no strong “must-buy-now” timing signal for an impatient entry.
Insider activity is a major red flag: insiders are selling, with selling up ~2723% over the last month.
Near-term event risk is elevated with earnings on 2026-02-19 (after hours) while fundamentals are already weakening.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Price context: $0.265 (+4.37%) while broader market is risk-off (S&P 500 -0.94%).
Trend: Bearish structure with moving averages stacked negatively (SMA_200 > SMA_20 > SMA_5), implying the dominant trend is still down.
MACD: Histogram -0.00128 (below 0) and negatively contracting → downside momentum persists, though selling pressure may be stabilizing rather than reversing.
RSI (6): 41.19 (neutral-to-weak) → not oversold enough to justify an impatient “dip buy,” and not strong enough to confirm a reversal.
Key levels:
- Resistance: Pivot 0.278, then R1 0.304 / R2 0.320.
- Support: S1 0.252, then S2 0.236.
- Practical read: price is below the pivot (0.278). Until it reclaims and holds above ~0.278–0.304, rallies are more likely to be sold.
Pattern-based odds provided: modeled 80% chance of +1.95% next day / +7.85% next week / +28.29% next month, but this conflicts with the current bearish trend signals—treat as secondary to actual momentum/MA structure.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Liquidity/sentiment snapshot:
- Open interest: Calls 347 vs Puts 4 → Put/Call OI ratio 0.01 (very call-skewed positioning).
- Volume: 0 today (calls and puts), despite 5D/10D avg volume ~42/38 → current session options activity is absent, so sentiment read is weak.
Volatility:
- 30D IV ~357% (extremely high) with HV ~58% → options are pricing very large moves; this often reflects micro-cap/event risk and can indicate poor pricing efficiency.
- IV trend: 5D avg ~362% vs 10D avg ~434% → still extreme, but cooling from prior levels.
Takeaway: Call-heavy open interest looks optimistic, but with zero volume today and extreme IV, the options market signal is not reliable for a confident bullish entry.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings on 2026-02-19 (after hours): could act as a catalyst if results/guidance surprise positively.
- Benchmark maintains a Speculative Buy rating (despite lowering the target), which can help sentiment in a thinly-followed micro-cap.
- Modeled candlestick-pattern projection provided indicates a statistical tilt to gains over 1W/1M (though not confirmed by trend indicators).

Neutral/Negative Catalysts

- Insiders are selling aggressively (selling amount up ~2723% last month) — strong negative signal for near-term confidence.
- Technical trend is bearish (SMA stack + MACD below zero); price is also below the pivot (0.278), suggesting overhead supply.
- Fundamentals are deteriorating (revenue down YoY; losses widened YoY; margins down YoY).
- No supportive news flow in the last week; absent catalysts can leave the stock drifting with the prevailing downtrend.
- Options show extreme IV and effectively no trading volume today → adds event-risk without providing a clean sentiment confirmation.
- Hedge funds: neutral with no notable recent trend — no institutional “sponsorship” signal.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $2,360,117, down -6.11% YoY → top-line shrinking.
Net income: -$1,153,959, down -21.03% YoY → losses widened.
EPS: -$0.01, down -50.00% YoY → per-share profitability trend deteriorating.
Gross margin: 68.67%, down -5.54% YoY → margin compression.
Overall: weakening growth and profitability into an upcoming earnings event (2026-02-19) is not a favorable “buy-now” setup for an impatient entry.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Latest update (2025-11-20): Benchmark lowered price target to $1.00 from $1.25, maintained Speculative Buy.
What changed: target cut was driven by elusive sales traction in the Medical business and lowered forward revenue estimates.
Wall Street pros view (bull case): still sees substantial upside vs the current ~$0.265 price, implying potential re-rating if traction improves.
Wall Street cons view (bear case): the target cut highlights execution risk and weak sales momentum; the “Speculative” framing signals elevated uncertainty.
Politicians/congress: No recent congress trading data available; no politician/influential-figure activity provided.

2 Analyst Rating

Wall Street analysts forecast MLSS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLSS is 1 USD with a low forecast of 1 USD and a high forecast of 1 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.255

Low

Averages

High

Current: 0.255

Low

Averages

High

Benchmark

Speculative Buy

downgrade

AI Analysis

2025-11-20

Reason